Abstract | PURPOSE: MATERIALS AND METHODS: The clinical records of 119 patients were included. The main outcome measurement was the occurrence of contralateral eye involvement. RESULTS: Over a mean follow-up period of 1.6 years, the overall incidence rate of contralateral involvement was 0.17/person-year. The cumulative incidence of contralateral involvement at 6 months and 1 year was 23.8% and 28.4%, respectively. Receiving HAART at the visit before the event was associated with a decreased risk of developing contralateral retinitis (hazard ratio [HR] = 0.26, P = 0.002). CONCLUSIONS: The use of HAART, associated with subsequent immune recovery, significantly reduced the incidence of contralateral eye involvement by approximately 75% among patients in our setting.
|
Authors | Wantanee Sittivarakul, Thanyapat Benjhawaleemas, Nipat Aui-Aree, Pichai Jirarattanasopa, Tippawan Liabsuetrakul |
Journal | Ocular immunology and inflammation
(Ocul Immunol Inflamm)
Vol. 24
Issue 5
Pg. 530-6
(Oct 2016)
ISSN: 1744-5078 [Electronic] England |
PMID | 26327465
(Publication Type: Journal Article)
|
Chemical References |
- Antiviral Agents
- Ganciclovir
|
Topics |
- AIDS-Related Opportunistic Infections
(drug therapy, epidemiology)
- Adult
- Antiretroviral Therapy, Highly Active
- Antiviral Agents
(therapeutic use)
- CD4 Lymphocyte Count
- CD4-Positive T-Lymphocytes
(immunology)
- Cohort Studies
- Cytomegalovirus Retinitis
(drug therapy, epidemiology)
- Eye Infections, Viral
(drug therapy, epidemiology)
- Female
- Follow-Up Studies
- Ganciclovir
(therapeutic use)
- Humans
- Incidence
- Intravitreal Injections
- Male
- Retrospective Studies
- Risk Factors
- Visual Acuity
|